Throw Away Junk Plans Act

HR 35, the Close the Medigap Act; HR 711, the Throw Away Junk Plans Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; S 652, the Safe Step Act; S 1214, the RARE Act; S 2243, the Palliative Care and Hospice Education and Training Act; draft legislation regarding Health Care Sharing Ministry transparency; Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements; Legislation to increase federal investment in Consumer Assistance Programs; FDA draft guidance related to dose optimization studies in clinical trials

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Treasury, Dept of, White House Office

HR 35, the Close the Medigap Act; HR 711, the Throw Away Junk Plans Act; HR 3991 / S 1624, the Gabriella Miller Kids First Act; HR 3503 / S 1701, The NIH Clinical Trial Diversity Act; S. 2039, The Cancer Drug Parity Act; HR 824, the Telehealth Benefit Expansion Act; HR 2868, the Association Health Plans; HR 2813, Self-Insurance Protection Act; HR 3799, CHOICE Arrangement Act; HR 4363 / S 2213, Comprehensive Cancer Survivorship Act; S 652, the Safe Step Act; S 1214, the RARE Act; The DIVERSE Trails Act (yet to be introduced); The DEPICT Act (yet to be introduced); Implementation of the FY23 omnibus, specifically provisions related to increasing access to clinical trials; Implementation of the No Surprises Act; Federal rulemaking related to Short-term Limited Duration Insurance (STLDI) plans; FDA regulatory action related to the safety of infusion bags of varying sizes; Insurance appeals and denials; Federal rulemaking related to Association Health Plans; Consumer protections related to consumers who will lose insurance due to the end of certain federal Medicaid maintenance-of-effort requirements;

Client expense: $480,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Treasury, Dept of, White House Office

Worked with Sen. Casey's and Sen. Fetterman's office in support of Medicare Advantage and requested both offices sign a bi-partisan letter to CMS requesting the preservation and strengthening of the MA program. Worked with Pennsylvania congressional delegation members to stress the importance of 12-month continuous eligibility for kids in the CHIP program and support for HR711. Also discussed importance of supporting the ability of DSNP to provide SDOH support to members. Worked with Congressman Cartwright's staff to seek support of the MA program and to highlight the negative impacts to GHP of the CMS proposed changes to the MA Risk Adjustment Model. Met with members of the Pennsylvania delegation and staff to stress the importance and update on the Medicaid eligibility redetermination process.

Client expense: $72,372 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE